Verzenio

 (abemaciclib) Eli Lilly

Composition:

• Available in film-coated tablet with each contains 100 mg or 150 mg of abemaciclib

Indication:

• Indicated for the treatment of women with hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone agonist

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.